20240018472. ENHANCEMENT OF EXTRACELLULAR VESICLE PRODUCTION BY LYSOSOME INHIBITOR simplified abstract (ExoTop Theragnostics Inc.)
Contents
ENHANCEMENT OF EXTRACELLULAR VESICLE PRODUCTION BY LYSOSOME INHIBITOR
Organization Name
Inventor(s)
ENHANCEMENT OF EXTRACELLULAR VESICLE PRODUCTION BY LYSOSOME INHIBITOR - A simplified explanation of the abstract
This abstract first appeared for US patent application 20240018472 titled 'ENHANCEMENT OF EXTRACELLULAR VESICLE PRODUCTION BY LYSOSOME INHIBITOR
Simplified Explanation
The patent application describes methods and systems for enhancing the production of high-quality extracellular vesicles (EVs) from mammalian cells. These methods involve culturing the cells in a chemically-defined protein-free (CDPF) medium and adding a lysosome inhibitor to increase EV production. The CDPF medium may also be supplemented with additives.
- Methods and systems for improving the production of extracellular vesicles (EVs) from mammalian cells are disclosed.
- The methods involve culturing the cells in a chemically-defined protein-free (CDPF) medium.
- The addition of a lysosome inhibitor is used to increase the production of EVs.
- The CDPF medium can be supplemented with additives to further enhance EV production.
Potential Applications:
- Biomedical research: The increased production of high-quality EVs can provide valuable material for studying various biological processes and diseases.
- Drug delivery: EVs can be used as carriers for delivering therapeutic molecules to target cells, potentially improving the efficacy and safety of drug delivery.
- Biomarker discovery: EVs contain various biomolecules that can serve as potential biomarkers for diagnosing diseases or monitoring treatment responses.
Problems Solved:
- Low yield of EVs: The methods described in the patent application aim to address the challenge of obtaining sufficient quantities of high-quality EVs for research and therapeutic applications.
- Contamination with unwanted proteins: The use of a chemically-defined protein-free medium helps minimize contamination with unwanted proteins, ensuring the purity and quality of the EVs produced.
Benefits:
- Increased production of high-quality EVs: The methods and systems described in the patent application can enhance the yield and quality of EVs, providing researchers and clinicians with a valuable resource for various applications.
- Improved drug delivery: EVs produced using these methods can potentially serve as more efficient and targeted drug delivery vehicles, improving therapeutic outcomes and reducing side effects.
- Enhanced biomarker discovery: The increased production of EVs with specific biomolecules can facilitate the discovery of novel biomarkers for disease diagnosis and monitoring.
Original Abstract Submitted
provided are methods and systems for an enriched production of high-quality extracellular vesicles (evs) from a mammalian cell. in some cases, the methods may comprise culturing the cell in a chemically-defined protein-free (cdpf) medium with the addition of a lysosome inhibitor to increase production of evs. in some cases, the cdpf medium is supplemented with additives.
